Brain Tumours

BRAFV600 Mutations –pHGG Target? • Good Target? • PROs – Established oncogene with known mechanism – Established clinical drugs & validated biomarkers – Proof of mechanism and concept proven in melanoma • CONs – Low prevalence in pHGG (6-8%)

– Target can be heterogenous in tumours – Resistance can be inherent or acquired